Chinese venture capital firm Qiming Venture Partners held the final close of its RMB Fund VI at RMB 2.852 billion.
Currently, Qiming has $5.9 billion in assets under management, targeting early-and-growth-stage healthcare and TMT investments.
Since inception in 2006, Qiming has invested in more than 380 companies, among which over 40 achieved unicorn status. They have exited investments in over 130 companies through IPO, M&A or other means. Notable exit deals include Xiaomi, Gan & Lee Pharmaceuticals, Meituan, Bilibili, RoboRock, TigerMed, Zai Lab, CanSino Biologics Inc., Venus Medtech, APT Medical, and so forth.
In 2020, the firm made over 70 investments and over 100 of existing portfolio companies completed new financing rounds. As of today, they have had 13 public listings in portfolio since 2020.
Qiming has offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston and the San Francisco Bay Area. Key people include Duane Kuang, Founding Managing Partner, and William Hu, Managing Partner.